CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab
2023/3720 UMBRELLA
Phase 3 small_molecule active
Quick answer
CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable, Tislelizumab for patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active